FDA May Downgrade Cancer Tests From Class III to II
Published Date: 11/12/2026
Proposed Rule
Summary
The FDA wants to change the rules for certain cancer test systems called immunohistochemistry (IHC) tests. These tests will move from a strict, expensive approval process (Class III) to a simpler, faster one (Class II) with special safety rules. This change affects companies making these tests and could speed up getting them to doctors and patients. Comments on this plan are open until January 11, 2027.
Analyzed Economic Effects
6 provisions identified: 5 benefits, 1 costs, 0 mixed.
IHC Oncology Tests Moved to Class II
FDA proposes to reclassify immunohistochemistry (IHC) test systems indicated for use with a corresponding approved oncology therapeutic product from class III (premarket approval) to class II (special controls) subject to premarket notification (510(k)). The proposal explicitly lists product codes MVC, NKF, QQT, NQF, PLS, PKW, QUL, QNH, QZJ, SBL, SER, and SHF as the devices affected.
510(k) Required Before Marketing
If the proposed order is finalized, persons who intend to market these oncology therapeutic IHC-based test systems must submit a premarket notification under section 510(k) of the FD&C Act and receive clearance prior to marketing the device. FDA is not proposing to exempt this device type from 510(k) requirements.
May Speed Patient Access to Tests
FDA states the reclassification to class II and use of the 510(k) pathway is less burdensome and generally results in a shorter premarket review timeline than a PMA, which FDA expects may provide more timely patient access and enable more manufacturers to develop these tests.
Existing PMA Devices Keep Authorization
Oncology therapeutic IHC-based test systems that have prior PMA approval at the time of the final order may continue to be marketed under their existing PMA and would not require an additional marketing authorization. However, changes or modifications that could significantly affect safety or effectiveness would generally require submission of a 510(k).
Use of Predetermined Change Control Plans
FDA notes manufacturers may use predetermined change control plans (PCCPs) authorized by FDA to implement future modifications described in the PCCP without submitting a new 510(k) for each change, under section 515C of the FD&C Act as added by FDORA. FDA reviews a PCCP as part of a marketing submission to ensure continued safety and effectiveness.
Devices Identified as Prescription IVDs
Under the proposed order, oncology therapeutic IHC-based test systems would be identified as prescription in vitro diagnostic (IVD) devices and would be subject to prescription labeling requirements for IVD products (see 21 CFR 809.10(a)(4) and (b)(5)(ii)).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22944, Modification to Work Requirements for Able-Bodied Adults
This new rule changes work requirements for able-bodied adults on SNAP, giving some people more time before they lose benefits if they don’t work or train. It updates who can skip the time limit, adds special exceptions for Alaska and Hawaii, and tightens rules for requesting waivers. These changes could affect many SNAP participants starting after the rule is finalized, aiming to make the program fairer and clearer.
Next: 2026-23017, Amendment of Jet Route J-21 in the Vicinity of Laredo, TX
The FAA wants to fix Jet Route J-21 near Laredo, TX by straightening it and removing a tiny 1.47-degree turn. This change will make flights smoother and more efficient for pilots flying this route. If you have thoughts, send them in by December 28, 2026—no costs or delays expected!